RFLReal Estate · Real Estate ServicesRFL Stock Forecast: Rafael Holdings, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 15 Aug 2026 — in the lower half.
RFL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Rafael Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (87): The share price has been relatively steady.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
RFL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RFL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RFL appears on the weeks it earns a place.
RFL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Rafael Holdings, Inc. (RFL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 14.3×
- Price / sales
- 105.6×
- Price / book
- 1.4×
- EV / EBITDA
- −2.2×
Cheaper than 49% of US stocks
Cheaper than 4% of US stocks
Cheaper than 61% of US stocks
Cheaper than 72% of US stocks
- Revenue growth (YoY)
- −50.6%
- Earnings growth (YoY)
- 132.5%
- Gross margin
- 95.5%
- Operating margin
- −3838.0%
- Net margin
- 0.0%
Higher than 5% of US stocks
Higher than 87% of US stocks
Higher than 98% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
- Return on equity
- −37.6%
- Return on assets
- −22.8%
- Dividend yield
- 2576.6%
Higher than 25% of US stocks
Higher than 18% of US stocks
Higher than 99% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
RFL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rafael Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about RFL stock
How does Ticker Nerd's model rank RFL?
As at 15 Aug 2026, Rafael Holdings, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (87 of 100).
What is the RFL stock forecast for 2030?
No analyst covering Rafael Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RFL are extrapolating price history, which says nothing about the business.
How has RFL stock performed over the past year?
Rafael Holdings, Inc. returned +23.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rafael Holdings, Inc. do?
Rafael Holdings Inc. operates as a holding company with a focus on healthcare and real estate.
About Rafael Holdings, Inc.
Rafael Holdings Inc. operates as a holding company with a focus on healthcare and real estate. Its primary function is to invest in and support the development of biopharmaceutical ventures alongside managing a portfolio of commercial real estate properties. The company actively engages in the life sciences sector, where it holds interests in entities exploring innovative cancer and metabolic disease therapies. These ventures reflect its strategic aim to contribute to groundbreaking medical advancements. In addition to its biopharmaceutical interests, Rafael Holdings owns and oversees office buildings situated primarily in Newark, New Jersey. This dual focus on both healthcare innovations and real estate investments underscores the company's diversified business model. By balancing real estate stability with potential high-growth healthcare opportunities, Rafael Holdings positions itself uniquely within the financial market. It serves as a bridge between traditional real estate investment and cutting-edge biotech endeavors, leveraging its resources to create value across different sectors. As a public company, Rafael Holdings offers investors exposure to both tangible property assets and pioneering medical technology developments, reflecting its integral role in advancing healthcare solutions while maintaining a solid real estate foundation.
CEO Mr. Howard S. Jonas · 21 employees · United States · https://www.rafaelholdings.com